<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520062</url>
  </required_header>
  <id_info>
    <org_study_id>LIRAP</org_study_id>
    <nct_id>NCT03520062</nct_id>
  </id_info>
  <brief_title>The Effect of Liraglutide on Pancreatic Hormones and Its Size</brief_title>
  <acronym>LIRAP</acronym>
  <official_title>The Effect of Liraglutide on Pancreatic Hormones and Its Size</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicolai Jacob Wewer Albrechtsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone used to treat type 2 diabetes
      and severe overweight (Liraglutide).The two pancreas enzymes: amylase and lipase are slightly
      elevated in GLP-1 treated compared with placebo-treated individuals. Increased levels of
      these two enzymes (amylase and lipase) are associated with acute inflammation of the pancreas
      (acute pancreatitis). In humans treated with GLP-1 (receptor agonist) there have not been
      found an increased risk of acute pancreatitis.

      Animal and cell studies have shown that the increased levels of amylase and lipase in the
      blood are not due to an inflammatory state but adaptive changes (volume increase) of the
      pancreas.

      The investigators (professor Jens Juul Holst, professor Sten Madsbad) want to investigate
      whether the increased levels of amylase and lipase in the blood of individuals treated with
      the GLP-1 analogue Saxenda are due adaptive changes of the pancreas. This will be achieved by
      measuring amylase and lipase before, during and after treatment with a GLP-1 receptor
      agonist, and at the same time use advanced scanning equipment (PET-MR) from the Clinical
      Physiological and Nuclear Medical Department at Rigshospitalet, which can determine any
      volumetric changes in the pancreas with high reproducibility.

      The scan will be centered on the pancreas, other organs are not evaluated why the study is
      not designed to detect any malignant findings in the pancreas or other organs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volumetric Changes of the Pancreas</measure>
    <time_frame>6 weeks</time_frame>
    <description>Measurements of the pancreas volumen using magnetic resonance imaging-positron emission tomography based technology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Plasma Concentrations of Pancreatic Amylase and Lipase</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body weight</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glycemic index</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of glucagon, insulin and citrullin</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of the drug</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other MR based changes in the pancreas (edema, cellularity and structural changes)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uptake of fluorothymidine tracer in the pancreas measured by PET</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>GLP-1 Receptor Agonist (Liraglutide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0mg daily dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml</intervention_name>
    <description>Treatment with Liraglutide (3.0mg per day) for ~6 weeks</description>
    <arm_group_label>GLP-1 Receptor Agonist (Liraglutide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI â‰¥ 26 og &lt; 50 kg/m2

        Exclusion Criteria:

          -  Abdominal Diameter &gt;60cm type 1 or type 2 diabetes Heart Failure or Disease Statins
             Kidney or Liver disease Thyroid Disease Inflammatory Bowel Disease Gastroparesis
             Cancer Lung disease Psychiatric disease Gastric Bypass operation Previous pancreatitis
             Increased alcoholic consumption Familiar incidence of multiple endocrine neoplasia
             Previous treatment with GLP-1 (incretin) based medicine Pacemaker or other
             non-MR-compatible devices
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicolai Albrechtsen, MD, PhD</last_name>
    <phone>+4529649329</phone>
    <email>hgk795@ku.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jens Holst, MD, DMSci</last_name>
    <phone>+45 28 75 75 18</phone>
    <email>jjholst@sund.ku.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Endocrinology</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sten Madsbad, MD, DMSci</last_name>
      <phone>38622291</phone>
      <email>Sten.Madsbad@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Maria Svane, MD</last_name>
      <phone>38626357</phone>
      <email>mariasvane@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Nicolai Jacob Wewer Albrechtsen</investigator_full_name>
    <investigator_title>Postdoc, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Amylase</keyword>
  <keyword>Lipase</keyword>
  <keyword>GLP-1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We have yet not decided to share IPD as this also would require approval from the ethical and data approval comite</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

